Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Papillary thyroid carcinoma, Non-medullary thyroid carcinoma, and Follicular thyroid carcinoma.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Hormones | 3 | Papillary thyroid carcinoma, Non-medullary thyroid carcinoma, Follicular thyroid carcinoma |
HRAS-related Costello syndrome (Costello syndrome) affects multiple organ systems. The typical presentation is characterized by diffuse hypotonia and severe feeding difficulties in infancy; short stature; developmental delay or intellectual disability; characteristic facial features; curly or sparse, fine hair; loose, soft skin with deep palmar and plantar creases; papillomata of the face and perianal region; joint laxity with ulnar deviation of the wrists and fingers; tight Achilles tendons; and cardiac involvement (including hypertrophic cardiomyopathy [HCM], congenital heart defects, and arrhythmia). Postnatal cerebellar overgrowth can result in Chiari I malformation with associated hydrocephalus or syringomyelia. There is an approximate 15% lifetime risk for malignant tumors in individuals with Costello syndrome including rhabdomyosarcoma and neuroblastoma in young children and transitional cell carcinoma of the bladder in adolescents and young adults. To date, more than 100 individuals have been identified with a pathogenic variant in HRAS [, , , , , , ]. The following description of the phenotypic features associated with this condition is based on these reports. Table 2. Costello Syndrome: Frequency of Select Features
Feature | % or # of Persons w/Feature | Comment |
|---|---|---|
Failure to thrive | 95% | Failure to thrive is typical in infancy. |
Short stature | 95% | Stature typically remains short, even w/GH treatment. Gastrointestinal/ feeding |
G-tube requirement | 65% | Inability to eat by mouth is common throughout infancy early childhood.; Weight gain remains slow, even w/feeding tube use high caloric intake. Pyloric stenosis |
Hypotonia | 70% | — |
Chiari I malformation | 50% | Chiari I malformation may develop over time. |
Seizures | 25% | Diagnosis of seizures should prompt investigation for hypoglycemia . Cardiac |
Arrhythmia | 55% | — |
HCM | 60% | — |
Pulmonic valve stenosis | 10% | — |
Aortic dilatation | 5%-10% | — |
Atrial septal defects | 5%-7% | — |
Developmental delay | 95% | — |
Intellectual disability | 80% | — |
Anxiety | 65% | Dermatologic |
Papillomata | 50%-60% | — |
Callouses | 65% | Musculoskeletal |
Hip dysplasia | 17%-45% | — |
Osteopenia | 45% | — |
Scoliosis/kyphosis | 17%-75% | Scoliosis kyphosis may increase w/age. |
Ulnar deviation of fingers | 82% | — |
Elbow contractures | 53% | — |
Obstructive sleep apnea | 7/10 | — |
GH deficiency | 45% | — |
Solid tumors (overall risk incl rhabdomyosarcoma, neuroblastoma, transitional cell carcinoma of bladder) | 15% | See . Vision issues |
Nystagmus | 40% | — |
Myopia | 60% | Genitourinary |
Cryptorchidism | 50% of males | — |
Renal anomalies | 50% | Based on , , , , , , , , , Growth. Increased birth weight and head circumference (often 50th centile) for gestational age can lead to the categorization of Costello syndrome as a macrosomia disorder, which is misleading. Increased birth weight is instead related to fetal hydrops. |
Source: GeneReviews — "HRAS-Related Costello Syndrome"
HRAS encodes HRas proto-oncogene, GTPase (189 aa). Involved in the activation of Ras protein signal transduction. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity
Thyroid cancer, nonmedullary, 2 is associated with mutations in the HRAS gene on chromosome 11.
The HRAS protein participates in S-farn Me-HRAS, -NRAS and -KRAS4A are palmitoylated pathway.
HRAS is classified as a druggable target (Clinically Actionable, Drug Resistance, Druggable Genome, Enzyme, and Tumor Suppressor categories) with score 0.8.
NRAS encodes NRAS proto-oncogene, GTPase (189 aa). Ras proteins bind GDP/GTP and possess intrinsic GTPase activity Highest expression in Cells EBV-transformed lymphocytes (77.3 TPM) and Cells Cultured fibroblasts (52.5 TPM).
Thyroid cancer, nonmedullary, 2 is associated with mutations in the NRAS gene on chromosome 1.
The NRAS protein participates in S-Farn-Me KRAS4A, HRAS, NRAS and S-Farn-Me PalmS KRAS4A,HRAS, NRAS pathways.
NRAS is classified as a druggable target (Clinically Actionable, Drug Resistance, and Enzyme categories) with score 0.8.
In a systematic review of 146 individuals with an HRAS pathogenic variant, there was no apparent correlation between the specific variant and the variables studied (HCM, multifocal tachycardia, aortic dilatation) . Because few affected individuals with HRAS pathogenic variants other than have been identified, limited genotype-phenotype correlations have been observed:
Source: GeneReviews — "HRAS-Related Costello Syndrome"
Penetrance for Costello syndrome is 100% to date [, , , ].
Source: GeneReviews — "HRAS-Related Costello Syndrome"
No consensus clinical diagnostic criteria for HRAS-related Costello syndrome (Costello syndrome) have been published to date.
Costello syndrome should be suspected in probands with the following clinical and neuroimaging findings and family history.
Clinical Findings
Prenatal findings
On ultrasound examination:
Increased nuchal thickness
Polyhydramnios (90%)
Characteristic ulnar deviation of the wrists
Short humeri and femurs
Fetal tachycardia (various forms of atrial tachycardia)
Preterm delivery
Postnatal findings
Severe postnatal feeding difficulties extending throughout early childhood
Failure to thrive
Short stature
Macrocephaly (relative or absolute)
Coarse facial features (See and .)
Curly or sparse, fine hair
Skin
Source: GeneReviews — "HRAS-Related Costello Syndrome"
No other loci have been identified as causative of HRAS-related Costello syndrome (Costello syndrome) . In earlier series, the 10%-15% of individuals suspected of having Costello syndrome who lacked an HRAS pathogenic variant were subsequently found to have cardiofaciocutaneous (CFC) syndrome or pathogenic variants in KRAS typical of Noonan syndrome . Note: While Costello syndrome is difficult to distinguish from CFC syndrome or Noonan syndrome in infants and young children, the distinction between Costello syndrome and Noonan syndrome is clearer in older children.
Table 3.
Disorders of Interest in the Differential Diagnosis of Costello Syndrome
Gene(s)/ Genetic Mechanism | Disorder | MOI | Clinical Features of Disorder
Overlapping w/Costello Syndrome | Distinguishing from Costello Syndrome
Source: GeneReviews — "HRAS-Related Costello Syndrome"
Genetic testing for HRAS, NRAS is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for thyroid cancer, nonmedullary, 2 has been reported in the published literature.
No approved treatments are currently available for thyroid cancer, nonmedullary, 2. The disease remains an area of unmet medical need.
Clinical practice guidelines for the management of HRAS-related Costello syndrome (Costello syndrome) have been published . Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with Costello syndrome, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. Costello Syndrome: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Measurement of height, weight, head circumference | Short stature FTT are common persist despite adequate caloric intake. Gastrointestinal/ |
Feeding | Assessment of nutritional status, feeding, GERD | Severe oral feeding difficulties are common in infants young children; a feeding tube is typically necessary.; FTT is common even with adequate caloric intake. |
Neurologic | Eval by neurologist for clinical signs of Chiari I malformation, tethered cord, /or syringomyelia | Brain MRI for Chiari I malformation; MRI radiographs of lower spine to assess for tethered cord; Spinal cord MRI if syringomyelia suspected EEG |
Development | Developmental assessment | To incl motor, adaptive, cognitive, speech-language eval; Eval for early intervention/ special education |
Cardiac |
Source: GeneReviews — "HRAS-Related Costello Syndrome"
Aggressive feeding therapy in infancy and early childhood is not likely to improve oral intake and may result in oral aversion. Neuroblastoma screening by measuring catecholamine metabolites is not helpful because elevated values were observed in individuals without an identifiable tumor.
Source: GeneReviews — "HRAS-Related Costello Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "HRAS-Related Costello Syndrome"
View trials for thyroid cancer, nonmedullary, 2
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 7. Costello Syndrome: Recommended Surveillance
System/Concern | Evaluation | Frequency |
|---|---|---|
Intellectual disability | Monitor developmental progress educational needs. | At diagnosis; thereafter at least annually in school-age persons |
Respiratory | Monitor for evidence of aspiration, respiratory insufficiency, obstructive sleep apnea. | At each visit |
Endocrine | Eval for neonatal hypoglycemia | Typical protocols for neonates at risk for hypoglycemia Eval for GH deficiency |
Tumor screening2 | Serial abdominal pelvic ultrasound screening for rhabdomyosarcoma neuroblastoma3 | Every 3-6 mos until age 8-10 yrs Urinalysis for hematuria to screen for bladder cancer |
Musculoskeletal | Baseline bone density assessment in those w/fractures | Depends on outcome of baseline study Orthopedic exam for possibility of developing hip d... |
Source: GeneReviews — "HRAS-Related Costello Syndrome"
No clinical trials have been registered for thyroid cancer, nonmedullary, 2.
314 publications have been identified in PubMed for thyroid cancer, nonmedullary, 2. Kisho has analyzed 138 by research type. Research spans Basic Science / Preclinical (30%), Epidemiology / Natural History (24%), and Diagnostic / Biomarker (15%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 42 | 30% |
Disease patterns and progression | 33 | 24% |
Testing and diagnosis research | 21 | 15% |
Research summaries | 17 | 12% |
Clinical study results | 17 | 12% |
Patient case studies | 5 | 4% |
New treatment approaches | 2 | 1% |
Other research | 1 | 1% |
Li X (2026). [PMID: 41494178](https://pubmed.ncbi.nlm.nih.gov/41494178/). *JMIR Cancer*. [Epidemiology / Natural History]
Qian C (2026). [PMID: 41954581](https://pubmed.ncbi.nlm.nih.gov/41954581/). *Endokrynol Pol*. [Diagnostic / Biomarker]
Yılmaz S (2026). [PMID: 41765079](https://pubmed.ncbi.nlm.nih.gov/41765079/). *J Vasc Interv Radiol*. [Clinical Trial Publication]
Thompson GR (2026). [PMID: 41083825](https://pubmed.ncbi.nlm.nih.gov/41083825/). *Ann Surg Oncol*. [Basic Science / Preclinical]
Scholfield DW (2026). [PMID: 41411004](https://pubmed.ncbi.nlm.nih.gov/41411004/). *JAMA Otolaryngol Head Neck Surg*. [Clinical Trial Publication]
Ahn JH (2026). [PMID: 40490622](https://pubmed.ncbi.nlm.nih.gov/40490622/). *Updates Surg*. [Basic Science / Preclinical]
Francis DO (2026). [PMID: 41733915](https://pubmed.ncbi.nlm.nih.gov/41733915/). *JAMA Netw Open*. [Epidemiology / Natural History]
Capitoli G (2025). [PMID: 40790099](https://pubmed.ncbi.nlm.nih.gov/40790099/). *Endocrine*. [Diagnostic / Biomarker]
Rocco D (2025). [PMID: 40869275](https://pubmed.ncbi.nlm.nih.gov/40869275/). *Int J Mol Sci*. [Basic Science / Preclinical]
Deziel NC (2025). [PMID: 40209106](https://pubmed.ncbi.nlm.nih.gov/40209106/). *Environ Health Perspect*. [Diagnostic / Biomarker]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 3:00 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Eval by cardiologist for congenital heart defects, HCM, arrhythmia
Standard eval |
Respiratory | Refer as needed to pulmonologist | Upper lower airway issues may occur; hypertrophy of tonsils adenoids may contribute to upper airway obstruction. |
Musculoskeletal | Eval by pediatric orthopedic surgeon | Assessment of spine extremities w/attention to hip joint abnormalities range of motion Genitourinary |
Eyes | Ophthalmology eval | Nystagmus vision disturbance are common.; Retinal dystrophy keratoconus are rare. |
Skin | Papillomata hyperkeratosis require referral to dermatologist. | Treat symptomatically. |
Dental | Eval by pediatric dentist is recommended. | Enamel defects malocclusion are common. |
Endocrine | Eval by endocrinologist for hypoglycemia GH deficiency | May require additional eval for dysregulated puberty Neurobehavioral/ |
Psychiatric | Neuropsychiatric eval as needed | In person age 4 yrs: screen for behavior issues incl sleep disturbances, ADHD, anxiety |
Tumor screening | Assess need for tumor screening. | Risk for embryonal rhabdomyosarcoma neuroblastoma in younger persons transitional cell carcinoma in older persons |
Genetic counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of CS to facilitate medical personal decision making Family support |
resources | By clinicians, wider care team, family support organizations | Assessment of family social structure to determine need for:; Community or such as Parent to Parent and Costello Syndrome Family Network; Social work involvement for parental support; Home nursing referral 1. |
Costello Syndrome: Targeted Therapy Treatment Class | Mechanism of Action | Specific Drug |
Kinase inhibitor | Reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) MEK2 activation; of MEK1 MEK2 kinase activity | Trametinib |